- Cancer Biology & Biomarkers
- Chromatography & Mass Spectrometry
- Contract Research, Clinical Trials and Outsourcing
- Drug Discovery
- Drug Targets
- Flow Cytometry
- Informatics & Lab Automation
- Ingredients, Excipients and Dosages
- Microbiology & RMMs
- NIR, PAT & QbD
- Raman Spectroscopy
- Screening, Assays & High-Content Analysis
- Thermal Processing
Open dialogue could improve type 2 diabetes management
16 September 2015 • Author: Victoria White
Results from Novo Nordisk‘s Perceptions of Control (POC) study, presented at the European Association for the Study of Diabetes (EASD) meeting, showed different perceptions of control among physicians and patients that may lead to suboptimal type 2 diabetes management.
The purpose of the study was to investigate how this patient population perceived control and whether it differed from perceptions of control among physicians. For the study, data were collected from 1,607 patients and physicians. The study showed adults with type 2 diabetes uncontrolled on basal insulin had a broader definition of control, perceived greater obstacles to maintaining control and that life was impacted significantly more than physicians expected.
“There is a significant gap in perceptions of control between physicians and patients in how they define control, the obstacles and how being uncontrolled on basal insulin impacts patients’ daily lives,” said Meryl Brod, PhD, lead investigator of the POC research study. “Having a more open dialogue during consultations may provide more insight into these critical factors which could improve diabetes management and lead to more effective individualised treatment plans.”
Patients perceived more obstacles to achieving control compared to physicians
The study identified that physicians defined control in measurable, clinical terms such as frequency/severity of hypoglycaemia (93% vs 69%), complications (89% vs 75%) and HbA1c (85% vs 79%) versus patients uncontrolled on basal insulin respectively. Although these clinical measures were important to people with type 2 diabetes, their definitions of control had a much broader focus than physicians and included the amount of insulin taken per day (78% vs 29%), energy levels (75% vs 33%) and how much they have to think about their disease (68% vs 31%) amongst other factors.
People with type 2 diabetes uncontrolled on basal insulin perceived more obstacles to achieving control compared to physicians, including stress (75% vs 54%), medicine side-effects (70% vs 56%) and a lack of patient support groups (56% vs 11%).
The impact of being uncontrolled on basal insulin and how it interfered in one’s life was perceived as significantly greater than physicians believed including aspects such as mood/emotions (63% vs 33%), making plans (62% vs 16%) and how much one accomplished during the day (62% vs 23%) amongst other factors.
ABB Analytical Measurement ACD/Labs ADInstruments Ltd Advanced Analytical Technologies GmbH Analytik Jena AG Astell Scientific Ltd B&W Tek Bachem AG Bibby Scientific Limited Bio-Rad Laboratories BioNavis Ltd Biopharma Group Black Swan Analysis Limited Butterworth Laboratories Ltd CAPSUGEL NV Charles Ischi AG | Kraemer Elektronik Cherwell Laboratories CI Precision Cobalt Light Systems Coulter Partners CPC Biotech srl Dassault Systèmes BIOVIA DiscoverX Edinburgh Instruments Enterprise System Partners (ESP) Eurofins BioPharma Product Testing EUROGENTEC F.P.S. Food and Pharma Systems Srl GE Analytical Instruments IDBS JEOL Europe Kaiser Optical Systems Inc. L.B. Bohle Maschinen + Verfahren GmbH Lab M Ltd. LabWare Linkam Scientific Instruments Limited Lonza MA Business Metrohm Molins Technologies Multicore Dynamics Ltd Nanosurf New England Biolabs, Inc. Ocean Optics Panasonic Biomedical Sales Europe B.V. Peak Scientific PerkinElmer Inc ReAgent Russell Finex Limited Source BioScience Takara Clontech Tornado Spectral Systems Tuttnauer Viavi Solutions, Inc Watson-Marlow Fluid Technology Group Wickham Laboratories Limited Xylem Analytics YMC Europe GmbH Yusen Logistics